Theramir marks the Kick-off of the EXCELL project

Theramir Ltd is pleased to have successful completed the kick-off meeting for its groundbreaking project EXCELL which was on January 17, 2025, at Theramir's headquarters in the ASBIS High Tech Cluster conference facilities.

The EXCELL project, supported by the European Union Recovery and Resilience Facility of the NextGenerationEU instrument through the Research and Innovation Foundation (IDEK), has received funding of €150,000 under the Call “POST-DOC/0524/0155”.

EXCELL aims to combine the expertise of each member of the Theramir team to explore the mode of action of EVmiR, Theramir’s patented technology, and its potential as treatment of bladder cancer. EVmiR is engineered to target aggressive, treatment-resistant and metastatic cancer - a group that encompasses more than 30 types of malignancies. This platform harnesses extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumors, where they target oncogenic proteins that fuel cancer cell proliferation.

The kick-off meeting served as the strategic platform for in-depth discussion and planning, outlining the project’s objective and milestones. The meeting involved a comprehensive presentation from Dr Marina Hadjicharalambous-Ryder, the project coordinator, which highlighted key goals and milestones of the project as well as the next steps ahead.

Dr. Marina Hadjicharalambous-Ryder, the scientific coordinator of the project along with Theramir’s team will drive the project and ensure its timely execution. Theramir’s scientific consortium consist of Dr Marianna Prokopi-Demetriades, co-founder and Director of Theramir and Theramir’s scientific team: Anna Katsioloudi, Dr Nikoletta Christodoulou and Giannis Andronikou.

Theramir Ltd expresses its commitment to advancing the field of cancer therapeutics as well as to achieving the project’s objectives and looks forward to the impactful outcomes that will emerge from the “EXCELL” project.

Co-founder wins Madame Figaro Award

Theramir’s cofounder, Dr. Prokopi-Demetriades, is the winner of this year’s MADAME FIGARO Cyprus Women of the Year Award, under the category INNOVATION, sponsored by Bank of Cyprus. The Madame Figaro Awards aim to acknowledge women who are pioneers in their respective fields and to celebrate their achievements and contributions to the world. See more at: https://www.madamefigaro.cy/i-dr-marianna-prokopi-dimitriadi-vrav/

Publication of Theramir's international patent application on miRNA therapeutics

Theramir’s international patent application titled “MicroRNA-based therapy targeted against LCP-1 positive cancers” has been published under the Patent Cooperation Treaty (PCT). The patent is now in the last stage of the PCT process before entering the national granting phase (expected in February 2021).

Theramir joins consortium of universities to secure €1m grant from the Research Promotion Foundation

A consortium comprised of the University of Cyprus, the Cyprus University of Technology, the European University of Cyprus and Theramir Ltd has been awarded an infrastructure grant from the Research Promotion Foundation to establish a joint “Center for Preclinical Evaluation and Optimization of Cancer Nanomedicines,” which aims to investigate nanoparticle formulations in the preclinical drug development stage. The project will be funded for 48 months under the RPF program call “New Strategic Infrastructure Units,” and has a total budget of €995,812.

Theramir participates in 1st Cancer Research Workshop organized by the Cancer Research Centre at CUT

Theramir recently took part in the 1st Cancer Research Workshop organized by the Cancer Research Centre, an initiative between the Cyprus University of Technology (CUT) and the German Oncology Center (GOC) in Limassol, Cyprus. The Centre was created to focus on critical issues relating to cancer diagnosis, treatment, care and prevention. A first-of-its kind hub in Cyprus for cancer research, the Centre will expedite the discovery of new diagnostic tools and treatments through a collaborative “bench-to-bedside” approach. The aim of the workshop was to initiate collaborations and explore ways in which high-quality basic research can be applied to clinical oncology, forming a bridge between CUT, GOC, international research centers of excellence and innovative biotechnology companies such as Theramir.

Theramir awarded a new grant by the Cyprus Research Promotion Foundation

Theramir Ltd has recently been awarded a grant from the Research Promotion Foundation (RPF) in collaboration with the Cyprus University of Technology (CUT) and the National Technical University of Athens (NTUA) to further advance its proprietary microRNA-based therapeutics targeted against specific proteins (oncoproteins) in cancer. The project will investigate a metastasis-specific miRNA biomarker and will develop Theramir’s therapeutic agents to target both primary tumors and metastatic focii in an animal model of breast cancer (breast to brain model). The project (acronym: MICROCURE) is funded through the RPF program call Didaktor, with a duration of 30 months and a total budget of €159,442. 

Theramir receives the ‘Innovative SME’ certification from the Ministry of Finance

We are pleased to announce that Theramir Limited has received the ‘Innovative SME’ certificate by the Ministry of Finance of the Republic of Cyprus, recognizing the company’s focus on innovation in the rapidly evolving field of precision oncology. Theramir was founded in 2017 in order to develop novel targeted therapies as part of a personalized medicine approach in the treatment of cancer disease, and is only the 2nd Cyprus based SME to be awarded the “Innovative SME” distinction. The certification, among other benefits, will allow prospective investors in Theramir to take advantage of the tax incentives for investments in innovative companies by claiming a tax deduction for the full amount of their investment (for up to 150K Euro per year). Innovative, research-intensive SMEs can also apply for grants of up to 2.5 million Euros for research and development projects through the EU’s Horizon 2020 program, while additional access to finance is available through local banks that offer Financial Risk-Sharing Products with the support of the European Investment Bank.